

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
27 July 2006 (27.07.2006)

PCT

(10) International Publication Number
WO 2006/078621 A3

(51) International Patent Classification:

C07D 417/12 (2006.01) C07D 277/42 (2006.01)
C07D 413/12 (2006.01) C07D 277/56 (2006.01)
C07D 401/12 (2006.01) C07D 513/04 (2006.01)
C07D 213/74 (2006.01) A61P 7/02 (2006.01)
C07D 417/14 (2006.01)

(21) International Application Number:

PCT/US2006/001535

(22) International Filing Date: 17 January 2006 (17.01.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/645,285 19 January 2005 (19.01.2005) US
60/749,317 9 December 2005 (09.12.2005) US

(71) Applicant (for all designated States except US): BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 And Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SUTTON, James, C. [US/US]; 8 Stonelea Drive, Princeton Junction, New Jersey 08550 (US). PI, Zulan [CN/US]; 52 Stanford Road East, Pennington, New Jersey 08534 (US). RUEL, Rejean [CA/CA]; 205 Macaulay, Sanit-lambert, Québec J4R 2H1 (CA). L'HEUREUX, Alexandre [CA/CA]; 40 Des Coniferes, Ste-julie, Québec J3E 3L8 (CA). THIBEAULT, Carl [CA/CA]; 2905 Rue Jules-roamins, Mascouche, Québec J7K 3Y3 (CA). LAM, Patrick, Y., S. [US/US]; 6 Ridgeway Drive, Chadds Ford, Pennsylvania 19317 (US).

(74) Agents: SUN, Jing G. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report
- with amended claims


(88) Date of publication of the international search report:

5 October 2006

Date of publication of the amended claims: 26 October 2006

[Continued on next page]

(54) Title: 2-PHENOXY-N- (1, 3, 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y₁ RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS



(57) Abstract: The present invention provides novel heteroaryl compounds of formula (Ia) which are selective inhibitors of the human P2Y₁ receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y₁ receptor activity. (Ia) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein: ring A is a 5- to 6-membered heteroaryl comprising: carbon atoms and 1-4 ringheteroatoms selected from N, NR¹¹, S(O)_p, and O, wherein said heteroaryl is substituted with 0-4 R⁷; ring B is phenyl substituted with 0-4 R⁷, pyridyl substituted with 0-3 R⁷, or thienyl substituted with 0-2 R⁷; X is NH or NMe; Y is O or S; R⁵ is a -(CR^fR^f)_n-C³-10 carbocycle substituted with 1-4 R^{5a}, or a -(CR^fR^f)_n-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR¹¹, O, and S(O)_p, wherein said heterocycle is substituted with 0-4 R^{5b}; the other substituents and variables are defined in the claims.



WO 2006/078621 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.